DX 182Alternative Names: DX-182
Latest Information Update: 12 Sep 2003
Price : $50 *
At a glance
- Originator Dyax
- Developer Dyax Corp.
- Class Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 18 Jul 2001 Preclinical development for Thrombosis (daignosis) in USA (unspecified route)